Health

  • April 14, 2026

    Ex-UCLA Gynecologist Pleads Guilty Before Sex Abuse Retrial

    A former University of California, Los Angeles, gynecologist on Tuesday pled guilty to sexually assaulting five patients and was once again sentenced to 11 years in prison, entering the plea at a pretrial hearing two months after a California appellate court tossed his initial convictions and ordered a new trial.

  • April 14, 2026

    States Denied Time For Talks To Settle Drug Price-Fixing Suit

    A Connecticut federal judge Tuesday denied a request by dozens of U.S. states to freeze their antitrust case against generic-drug manufacturers, a pause the states argued would allow the parties to focus on settlement talks rather than pending discovery and motion deadlines.

  • April 14, 2026

    Justices Told That Eli Lilly's FCA Qui Tam Challenge Too Late

    A whistleblower who secured a $183 million trial win against Eli Lilly urged the U.S. Supreme Court on Tuesday to reject its constitutional challenge over his ability to sue for the federal government, arguing the drugmaker's arguments came too late.

  • April 14, 2026

    Colo. Justices Weigh Bid To Restore Trans Youth Care

    Colorado's justices pushed Children's Hospital Colorado on Tuesday to explain how its decision to halt gender-affirming care for transgender youth patients is not discriminatory, even amid the federal government's threats to cut funding for providers that offer the care to children and adolescents.

  • April 14, 2026

    Trade Group Latest To Sue Wash. Over 340B Drug Pricing Law

    Pharmaceutical Research and Manufacturers of America claims a new Washington state law attempts to illegally reshape the federal 340B Drug Pricing Program and singles out participating drugmakers with burdensome regulations, according to a fresh federal lawsuit that follows similar constitutional challenges mounted by Novartis and AbbVie.

  • April 14, 2026

    Virginia Governor Proposes Delaying Cannabis Retail Sales

    Virginia Gov. Abigail Spanberger on Tuesday declined to sign into law legislation that would tax and regulate the sale of adult-use cannabis, sending the bill back to the Legislature with numerous changes, including delaying the launch of the retail market by an additional six months.

  • April 14, 2026

    EPA Sued Over Missed Deadline For Tougher Soot Limits

    A group of 17 organizations including the Sierra Club and the American Lung Association sued the head of the U.S. Environmental Protection Agency in California federal court Monday, alleging that the agency failed to meet a deadline to strengthen national air standards for soot.

  • April 14, 2026

    Ga. Providers Say Rutledge Bars United's Preemption Win

    Medical providers are urging a Georgia federal court to deny United's bid for an early win in its case seeking a declaration that the providers' purported attempt to claw back reimbursements for out-of-network services are preempted, arguing that state-law claims involving employee benefits aren't preempted by federal benefits law.

  • April 14, 2026

    Meta, Others Can't Look At Internal Data To Probe Jury Pool

    A California federal judge on Tuesday granted an uncontested bid by school district plaintiffs to bar Meta and other social media companies from using nonpublic information — including their internal data — to investigate potential jurors for an upcoming bellwether trial in multidistrict litigation over the alleged harms of social media addiction.

  • April 14, 2026

    Wash. Appeals Court Revives Podiatrist Trade Secrets Case

    An appeals court in Washington state has reinstated a case brought by a Seattle-area podiatry practice against a former employee accused of stealing patient data for his separate practice.

  • April 14, 2026

    FDA Offers Guidance On Safety Testing For Gene-Editing Tech

    The U.S. Food and Drug Administration on Tuesday issued draft guidance recommending steps drug companies should take to evaluate the safety of gene-editing technology as they seek federal approval for cutting-edge treatments aimed at genetic diseases.

  • April 14, 2026

    IHC's Ch. 11 Mediation Ask 'Jumped The Gun,' Creditors Say

    Lenders and unsecured creditors to Inspired Healthcare Capital have told a Texas bankruptcy court it is too soon in the senior-living facility group's Chapter 11 case to appoint a mediator, arguing its mandatory mediation proposal could bind creditors' rights.

  • April 14, 2026

    Eli Lilly To Purchase Cooley-Led CrossBridge In $300M Deal

    Venture-backed pre-clinical biotechnology firm CrossBridge Bio Inc., advised by Cooley LLP, on Tuesday announced that it has agreed to be bought by pharmaceutical giant Eli Lilly & Co. in a deal worth up to $300 million.

  • April 14, 2026

    7th Circ. Suggests High Court Ruling Supports Ark. PBM Rule

    The Seventh Circuit appeared reluctant Tuesday to revive a union fund's challenge to an Arkansas rule making health plans disclose pharmacy compensation and pay fees, with judges pointing to a 2020 U.S. Supreme Court ruling that permitted state cost regulations on pharmacy benefit managers.

  • April 14, 2026

    Ginsburg Hack Conviction Upheld For Man Who Blamed Cat

    The Fourth Circuit affirmed Tuesday a former hospital transplant coordinator's conviction for illegally accessing U.S. Supreme Court Justice Ruth Bader Ginsburg's healthcare records, upholding a ruling that the defendant was not improperly coerced when he told FBI agents a coworker or his cat may have been responsible.

  • April 14, 2026

    Mich. AG Says PBMs Can't Duck Drug-Pricing Suit

    Two pharmacy benefit managers can't dodge an antitrust lawsuit accusing them of price-fixing reimbursement rates because Michigan has properly claimed an antitrust violation, state Attorney General Dana Nessel told a federal court, asking it to toss aside the PBMs' dismissal bid. 

  • April 14, 2026

    4th Circ. Won't Rehear Allergan Overcharge Suit

    The Fourth Circuit on Tuesday denied a rehearing petition lodged after a panel revived a whistleblower suit accusing an Allergan Sales LLC predecessor of overcharging Medicaid.

  • April 14, 2026

    Buyers Seek Final Approval Of $4.85M Bayer Benzene Deal

    A class of consumers is asking a New Jersey federal court to give final approval of a $4.85 million settlement to resolve claims that Bayer US LLC's antifungal products were contaminated with benzene.

  • April 14, 2026

    Colo. Supplement Co. Sent Unwanted Texts, Suit Says

    A Colorado dietary supplement company violated the Telephone Consumer Protection Act by bombarding consumers with unsolicited telemarketing text messages despite their numbers being listed on the national Do Not Call Registry, according to a proposed class action filed Tuesday in Colorado federal court.

  • April 14, 2026

    Avanos Medical Going Private In $1.3B Deal Led By 3 Firms

    American Industrial Partners has agreed to acquire Avanos Medical Inc. in an all-cash transaction valued at nearly $1.3 billion, a take-private deal steered by three law firms, Avanos announced Tuesday. 

  • April 14, 2026

    State AGs, Albertsons Chain Reach $773M Opioid Deal

    Albertsons Cos. Inc. and the attorneys general of California, Colorado, Illinois and Oregon on Tuesday said that the pharmacy and grocery chain had agreed to a $773 million settlement in principle to end claims brought by states, local governments and Native American tribes over its role in the opioid crisis.

  • April 14, 2026

    Vehicle Co. Inks $150K Deal To End Tobacco Fee Suit

    International Motors LLC, formerly Navistar, has agreed to pay $150,000 to resolve a suit claiming the company illegally charged workers an extra $600 a year if they used tobacco without giving them a proper avenue to dodge the fee, according to an Illinois federal court filing.

  • April 14, 2026

    Omnicare OK'd For Ch. 11 Auction With $250M Base Bid

    Pharmacy services provider Omnicare's choice of a $250 million stalking horse bid for its assets was approved Tuesday by a Texas bankruptcy judge, setting up a possible auction in May.

  • April 14, 2026

    Screening Time Deal Doesn't Bar Break Suit, Wash. Panel Says

    An eldercare company's class settlement over COVID-19 screening time doesn't bar a separate suit claiming the company failed to pay workers for missed meal breaks, a Washington state appeals court ruled, reviving the break claims.

  • April 13, 2026

    Cannabis Giant Verano Accused Of Mishandling Patient Info

    Cannabis giant Verano exposed the private data of at least half a million of its medical marijuana customers, according to a proposed class action removed to federal court that alleges the company turned ordinary receipts into "highly sensitive medical records."

Expert Analysis

  • Series

    Podcasting Makes Me A Better Lawyer

    Author Photo

    Podcasting has changed how I ask questions and connect with people, sharpening my ability to listen without interrupting or prejudging, and bringing me closer to what law is meant to be: a human profession grounded in understanding, judgment and trust, says Donna DiMaggio Berger at Becker.

  • When Fraud Involvement Disqualifies FCA Whistleblowers

    Author Photo

    A Massachusetts federal court's recent dismissal of a False Claims Act relator in U.S. ex rel. Perry v. First Psychiatric Planners provides instructive insight into when whistleblowers may be denied their share of settlement proceeds, even if their involvement in the underlying fraud is a step removed, say attorneys at Holland & Knight.

  • Job Shift Accommodation Ruling Clarifies 'Essential Function'

    Author Photo

    In Siebrecht v. Mercy Health-Iowa, the Eighth Circuit's recent denial of a disabled worker's shift exemption request shows that the essential function of a job can encompass more than core job requirements and include things like scheduling flexibility, says Kim Kirn at Miles Mediation & Arbitration.

  • Opinion

    Fed. Circ. Must Bury Design Patent Doctrinal Zombies

    Author Photo

    After recently finding noninfringement in Range of Motion Products v. Armaid, the Federal Circuit must rehear the case to confront two troublesome doctrines of design patent law claim construction — feature filtration and claim verbalization — that have lingered for decades and intensified in recent years, say attorneys at McAndrews Held.

  • H-1B Registration Tips For New Wage-Weighted Selection

    Author Photo

    Practitioners participating in this year’s H-1B visa registration, currently underway, must understand that under the new wage-weighted selection process that replaced the random lottery, the crucial first step is choosing the correct standard occupational classification, says Jimmy Lai at Lai & Turner.

  • Lessons From Justices' Split On Major Questions Doctrine

    Author Photo

    The justices' varied opinions in Learning Resources v. Trump, which held the International Emergency Economy Powers Act did not confer the power to impose tariffs, offer a meaningful window into the U.S. Supreme Court's perspective on the major questions doctrine that will likely shape lower courts' approach to executive action challenges, say attorneys at Venable.

  • Drug Wholesaler's DPA Shows Imperfect Efforts Still Count

    Author Photo

    Atlantic Biologicals’ recent deferred prosecution agreement with federal prosecutors for allegedly distributing controlled substances to pill mill pharmacies demonstrates that even subpar cooperation, when combined with genuine remediation and strategic advocacy, can yield outcomes that protect a company's long-term interests, says Jonathan Porter at Husch Blackwell.

  • Key Takeaways As HRSA Aims To Revive 340B Rebate Pilot

    Author Photo

    The U.S. Department of Health and Human Services' recent request for feedback on the 340B Rebate Model Pilot Program demonstrates that it intends to correct the model's procedural defects, which is positive news for participating manufacturers, but a setback for covered entities, say attorneys at Manatt.

  • Why Mukherji Won't End USCIS' EB-1A Two-Step

    Author Photo

    A Nebraska federal court's recent decision in Mukherji v. Miller seemed to vindicate longstanding complaints about the U.S. Citizenship and Immigration Services' controversial two-step adjudication process, declaring the framework unlawful — but Mukherji is unlikely to be the death blow that immigration practitioners have hoped for, says Jun Li at Reid & Wise.

  • Unique Issues Facing Brand-Compounder Patent Litigation

    Author Photo

    Recent litigation and potential enforcement action against Hims & Hers Health raise questions about how compounders and branded pharmaceuticals companies would be positioned in patent litigation as compared to generics companies, which would require strategies different from those that would be used in traditional Hatch-Waxman Act litigation, say attorneys at Morgan Lewis.

  • Series

    Volunteering With Scouts Makes Me A Better Lawyer

    Author Photo

    Serving as an assistant scoutmaster for my son’s troop reaffirmed several skills and principles crucial to lawyering — from the importance of disconnecting to the value of morality, says Michael Warren at McManis Faulkner.

  • Series

    Law School's Missed Lessons: In Court, It's About Storytelling

    Author Photo

    Law school provides doctrine, cases and hypotheticals, but when lawyers step into the courtroom, they must learn the importance of clarity, credibility, memorability and preparation — in other words, how to tell simple, effective stories, say Nicholas Steverson and Danielle Trujillo at Wheeler Trigg, and Lisa DeCaro at Courtroom Performance.

  • Pros And Cons Of FDA's Push For Nonprescription Drugs

    Author Photo

    The U.S. Food and Drug Administration's recent moves to shift more prescription drugs to over-the-counter status could increase access to important medications, but also bring potential safety risks and other trade-offs for drug companies, say attorneys at Hogan Lovells.

  • Prepping For The Future Of No Surprises Act Enforcement

    Author Photo

    This year is expected to be a transition point for the No Surprises Act framework from regulatory delay to operational enforcement, so stakeholders should use this time to stress-test systems, clean up processes and prepare for enforcement, say attorneys at Akerman.

  • High Court's 'Skinny Label' Case May Tackle Wider Questions

    Author Photo

    The U.S. Supreme Court's upcoming decision in Hikma v. Amarin will have important ramifications for broader debates over what defines a generic version of a drug, and the pending case is already altering patent practice, say attorneys at Taft.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Health archive.